Rani Therapeutics (RANI) News Today → The best trading indicator for TSLA (From WealthPress) (Ad) Free RANI Stock Alerts $5.22 -0.24 (-4.40%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | globenewswire.comRani Therapeutics to Participate in May Investor ConferencesMay 13, 2024 | americanbankingnews.comRani Therapeutics (NASDAQ:RANI) PT Raised to $14.00 at BTIG ResearchMay 13, 2024 | americanbankingnews.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) to Post FY2026 Earnings of ($0.75) Per Share, Zacks Small Cap ForecastsMay 12, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Short Interest Down 27.9% in AprilRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 1,240,000 shares, a drop of 27.9% from the April 15th total of 1,720,000 shares. Currently, 10.9% of the shares of the company are short sold. Based on an average daily trading volume, of 144,600 shares, the days-to-cover ratio is currently 8.6 days.May 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Warby Parker (WRBY) and Adaptive Biotechnologies (ADPT)May 12, 2024 | americanbankingnews.comAnalysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.20May 9, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) PT Raised to $14.00BTIG Research boosted their target price on shares of Rani Therapeutics from $7.00 to $14.00 and gave the stock a "buy" rating in a report on Thursday.May 9, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Buy" from AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among aMay 9, 2024 | msn.comRANI: 1Q:24 ResultsMay 9, 2024 | globenewswire.comRani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024May 9, 2024 | americanbankingnews.comRani Therapeutics (NASDAQ:RANI) PT Raised to $13.00May 8, 2024 | markets.businessinsider.comEdward Nash Maintains Buy Rating on Rani Therapeutics Amid Strong Financials and Promising Clinical TrialsMay 7, 2024 | finance.yahoo.comRani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic UpdatesMay 7, 2024 | marketbeat.comHC Wainwright Raises Rani Therapeutics (NASDAQ:RANI) Price Target to $13.00HC Wainwright boosted their target price on shares of Rani Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday.May 6, 2024 | investorplace.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024May 6, 2024 | globenewswire.comRani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate UpdateMay 2, 2024 | finance.yahoo.comFavourable Signals For Rani Therapeutics Holdings: Numerous Insiders Acquired StockApril 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)April 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)April 14, 2024 | seekingalpha.comRANI Rani Therapeutics Holdings, Inc.April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)March 27, 2024 | marketbeat.comCanaccord Genuity Group Trims Rani Therapeutics (NASDAQ:RANI) Target Price to $9.00Canaccord Genuity Group dropped their price target on Rani Therapeutics from $21.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday.March 27, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Recommendation of "Buy" by AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 moMarch 25, 2024 | markets.businessinsider.comBuy Rating for Rani Therapeutics: Promising Clinical Data and Significant Market PotentialMarch 25, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) PT Lowered to $12.00 at HC WainwrightHC Wainwright reduced their price target on shares of Rani Therapeutics from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Monday.March 22, 2024 | seekingalpha.comRani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comRANI: 2023 ResultsMarch 21, 2024 | finance.yahoo.comQ4 2023 Rani Therapeutics Holdings Inc Earnings CallMarch 21, 2024 | finance.yahoo.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comRANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023March 20, 2024 | benzinga.comRecap: Rani Therapeutics Hldgs Q4 EarningsMarch 20, 2024 | globenewswire.comRani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate UpdateMarch 19, 2024 | benzinga.comEarnings Outlook For Rani Therapeutics HldgsMarch 16, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)March 16, 2024 | finance.yahoo.comRANI Apr 2024 2.500 putMarch 15, 2024 | finance.yahoo.comRANI Apr 2024 5.000 putMarch 15, 2024 | globenewswire.comRani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)March 12, 2024 | finance.yahoo.comIndividual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the companyMarch 2, 2024 | marketbeat.comRani Therapeutics (NASDAQ:RANI) Stock Price Down 1.3%Rani Therapeutics (NASDAQ:RANI) Shares Down 1.3%February 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Arcus Biosciences (RCUS) and United Therapeutics (UTHR)February 20, 2024 | finance.yahoo.comRANI: INITIATION – Realizing Oral Administration of BiologicsFebruary 19, 2024 | bizjournals.comSilicon Valley businesswomen share thoughts on mentoringFebruary 9, 2024 | marketbeat.comWedbush Analysts Lower Earnings Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Analysts at Wedbush decreased their FY2027 earnings per share (EPS) estimates for shares of Rani Therapeutics in a report issued on Tuesday, February 6th. Wedbush analyst A. Argyrides now anticipates that the company will earn ($1.78)February 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics Holdings on Strong Clinical and Strategic ProspectsFebruary 6, 2024 | msn.comRani Therapeutics Reports Positive Phase 1 Trial OutcomesFebruary 6, 2024 | msn.comRani Therapeutics Shares Exciting Clinical Trial ResultsFebruary 6, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for Rani Therapeutics (NASDAQ:RANI)Wedbush restated an "outperform" rating and issued a $8.00 price objective on shares of Rani Therapeutics in a research report on Tuesday.February 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics on Strong Clinical and Strategic MilestonesFebruary 5, 2024 | marketwatch.comRani Therapeutics Sees Positive Results From Trial for CT-P43 Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Millionaire Investor makes surprising election prediction (Ad)Millionaire Investor Makes Surprising Election Prediction Louis Navellier says he knows who's going to win the election. And how they could send six specific AI stocks through the roof on their first day. Click here for the full story… RANI Media Mentions By Week RANI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼0.960.50▲Average Medical News Sentiment RANI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼92▲RANI Articles Average Week Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AQST News CRMD News VTYX News NATR News NLTX News ME News INZY News XOMA News VNDA News ENTA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
